AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|AAPL333.74+0.48 (+0.14%) ▲|ABBV254.49+0.10 (+0.04%) ▲|ABT100.68+1.85 (+1.87%) ▲|ACN143.57-1.04 (-0.72%) ▼|ADBE237.25+1.94 (+0.82%) ▲|AMAT529.66-31.27 (-5.57%) ▼|AMD495.76-5.18 (-1.03%) ▼|AMGN366.29-5.29 (-1.42%) ▼|AMT170.06+1.14 (+0.67%) ▲|AMZN247.23-2.66 (-1.06%) ▼|AVGO370.83-3.63 (-0.97%) ▼|AXP355.35-6.22 (-1.72%) ▼|BA214.03-0.31 (-0.14%) ▼|BAC61.27-0.22 (-0.36%) ▼|BKNG181.68-2.93 (-1.59%) ▼|BLK1,072.20-14.85 (-1.37%) ▼|BMY60.74+0.23 (+0.38%) ▲|BNY157.13-3.73 (-2.32%) ▼|BRK-B490.91-2.21 (-0.45%) ▼|C129.36-2.35 (-1.78%) ▼|CAT880.28+3.11 (+0.35%) ▲|CL92.98-1.09 (-1.16%) ▼|CMCSA23.79-0.31 (-1.29%) ▼|COF208.03-3.90 (-1.84%) ▼|COP114.71+1.87 (+1.66%) ▲|COST940.87-4.70 (-0.50%) ▼|CRM170.77-1.91 (-1.11%) ▼|CSCO111.94+2.28 (+2.08%) ▲|CVS107.47+0.97 (+0.91%) ▲|CVX187.38+3.52 (+1.91%) ▲|DE597.24-1.73 (-0.29%) ▼|DHR203.83-1.18 (-0.58%) ▼|DIS97.67-2.04 (-2.05%) ▼|DUK125.01-1.10 (-0.87%) ▼|EMR139.54+0.46 (+0.33%) ▲|FDX312.98-5.22 (-1.64%) ▼|GD368.58-0.24 (-0.07%) ▼|GE348.83+3.10 (+0.90%) ▲|GEV1,057.84+21.62 (+2.09%) ▲|GILD134.28-2.02 (-1.48%) ▼|GM76.07-1.65 (-2.12%) ▼|GOOG346.12-7.69 (-2.17%) ▼|GOOGL346.77-7.69 (-2.17%) ▼|GS1,065.22-30.24 (-2.76%) ▼|HD338.87-9.15 (-2.63%) ▼|HON225.02-1.31 (-0.58%) ▼|IBM212.67-6.38 (-2.91%) ▼|INTC95.04-1.94 (-2.00%) ▼|INTU291.09-3.70 (-1.26%) ▼|ISRG345.42-56.91 (-14.15%) ▼|JNJ253.04+3.07 (+1.23%) ▲|JPM341.10-2.05 (-0.60%) ▼|KO81.56-3.36 (-3.96%) ▼|LIN513.22-7.52 (-1.44%) ▼|LLY1,179.11+9.94 (+0.85%) ▲|LMT508.77-4.75 (-0.93%) ▼|LOW208.73-7.43 (-3.44%) ▼|LRCX313.30-7.66 (-2.39%) ▼|MA543.60-7.94 (-1.44%) ▼|MCD267.71-5.75 (-2.10%) ▼|MDLZ61.00-0.42 (-0.68%) ▼|MDT83.20-0.36 (-0.43%) ▼|META646.01-18.53 (-2.79%) ▼|MMM159.84-1.93 (-1.19%) ▼|MO74.21+1.18 (+1.62%) ▲|MRK127.50-0.13 (-0.10%) ▼|MS215.50-2.87 (-1.31%) ▼|MSFT393.82-7.28 (-1.82%) ▼|MU848.95-4.25 (-0.50%) ▼|NEE88.80-0.55 (-0.62%) ▼|NFLX68.95-5.40 (-7.26%) ▼|NKE43.76-0.81 (-1.82%) ▼|NOW103.24-0.77 (-0.74%) ▼|NVDA202.81-4.59 (-2.21%) ▼|ORCL126.41+2.20 (+1.77%) ▲|PEP137.12-2.31 (-1.66%) ▼|PFE25.05-0.09 (-0.36%) ▼|PG149.98-1.52 (-1.00%) ▼|PLTR132.38-2.06 (-1.53%) ▼|PM192.98+3.14 (+1.65%) ▲|QCOM171.78+1.11 (+0.65%) ▲|RTX193.51-0.85 (-0.44%) ▼|SBUX105.49-2.88 (-2.66%) ▼|SCHW101.56-1.24 (-1.21%) ▼|SO95.30-0.77 (-0.80%) ▼|SPG228.70+0.21 (+0.09%) ▲|T21.81-0.17 (-0.77%) ▼|TMO532.48-10.71 (-1.97%) ▼|TMUS192.43-0.42 (-0.22%) ▼|TSLA380.84-10.22 (-2.61%) ▼|TXN284.02-7.20 (-2.47%) ▼|UBER72.46-1.58 (-2.13%) ▼|UNH426.09+2.71 (+0.64%) ▲|UNP301.75+2.33 (+0.78%) ▲|UPS117.72+0.54 (+0.46%) ▲|USB63.14-0.87 (-1.36%) ▼|V358.56-6.58 (-1.80%) ▼|VZ43.59-0.29 (-0.66%) ▼|WFC87.51-0.56 (-0.64%) ▼|WMT114.24-0.71 (-0.62%) ▼|XOM147.36+1.41 (+0.97%) ▲|
22.8 C
New York
Saturday, July 18, 2026

Tag: clinical trials

newssourceFORcompanyinformationcontent1releasesmarket

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

AMF Regulated Information
Châtillon, France, July 6, 2026

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 26, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on June 19, 2026, the Organization and Compensation Committee of...

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

BALA CYNWYD, Pa., June 26, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host an investor event to discuss updates for the Company’s nomlabofusp clinical development program including a regulatory update and data from the ongoing long-term open label study for the treatment of Friedreich’s ataxia on Monday, June 29, 2026 at 7:45 am ET.

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report,...

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulations Plus Inc., Dassault Systèmes SE (SIMULIA/BIOVIA), Ansys Inc., Medidata Solutions (Dassault Systèmes), Insilico Medicine Ltd., Unlearn.AI Inc., Applied BioMath LLC, Rosa & Co. LLC, Entelos Inc., Pharsight Corporation (Certara) and others. 
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global In Silico Clinical Trials Market size & share revenue was valued at approximately USD 1.84 Billion in 2025 and is expected to reach USD 2.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 15.2% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Certara Inc., Simulations Plus Inc., Dassault Systèmes SE (SIMULIA/BIOVIA), Ansys Inc., Medidata Solutions (Dassault Systèmes), Insilico Medicine Ltd., Unlearn.AI Inc., Applied BioMath LLC, Rosa & Co. LLC, Entelos Inc., Pharsight Corporation (Certara) and others.

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease

PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with potential target engagementFindings support continued...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trials

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers